Ferrero JM - Search Results

1

Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016.

Deluche E, Antoine A, Bachelot T, Lardy-Cleaud A, Dieras V, Brain E, Debled M, Jacot W, Mouret-Reynier MA, Goncalves A, Dalenc F, Patsouris A, Ferrero JM, Levy C, Lorgis V, Vanlemmens L, Lefeuvre-Plesse C, Mathoulin-Pelissier S, Petit T, Uwer L, Jouannaud C, Leheurteur M, Lacroix-Triki M, Courtinard C, Perol D, Robain M, Delaloge S. Deluche E, et al. Among authors: ferrero jm. Eur J Cancer. 2020 Apr;129:60-70. doi: 10.1016/j.ejca.2020.01.016. Epub 2020 Mar 2. Eur J Cancer. 2020. PMID: 32135312

2

[Epidemiology of cancer of the breast].

Ferrero JM, Namer M. Ferrero JM, et al. Arch Anat Cytol Pathol. 1994;42(5):198-205. Arch Anat Cytol Pathol. 1994. PMID: 7872810 Review. French.

3

[Value of neo-angiogenesis evaluation in cancer of the breast].

Namer M, Ettore R, Pivot X, Ferrero JM, Teissier E. Namer M, et al. Among authors: ferrero jm. Bull Cancer. 1996 Dec;83(12):1041-2. Bull Cancer. 1996. PMID: 9116372 French. No abstract available.

4

[Prognostic factors and therapeutic strategy of breast cancer].

Namer M, Ramaioli A, Hery M, Ferrero JM. Namer M, et al. Among authors: ferrero jm. Rev Prat. 1998 Jan 1;48(1):45-51. Rev Prat. 1998. PMID: 9781209 Review. French.

5

Application of an original RT-PCR-ELISA multiplex assay for MDR1 and MRP, along with p53 determination in node-positive breast cancer patients.

Ferrero JM, Etienne MC, Formento JL, Francoual M, Rostagno P, Peyrottes I, Ettore F, Teissier E, Leblanc-Talent P, Namer M, Milano G. Ferrero JM, et al. Br J Cancer. 2000 Jan;82(1):171-7. doi: 10.1054/bjoc.1999.0896. Br J Cancer. 2000. PMID: 10638986 Free PMC article.

6

P53 determination alongside classical prognostic factors in node-negative breast cancer: an evaluation at more than 10-year follow-up.

Ferrero JM, Ramaioli A, Formento JL, Francoual M, Etienne MC, Peyrottes I, Ettore F, Leblanc-Talent P, Namer M, Milano G. Ferrero JM, et al. Ann Oncol. 2000 Apr;11(4):393-7. doi: 10.1023/a:1008359722254. Ann Oncol. 2000. PMID: 10847456 Free article.

7

Single-agent gemcitabine is active in previously treated metastatic breast cancer.

Spielmann M, Llombart-Cussac A, Kalla S, Espié M, Namer M, Ferrero JM, Diéras V, Fumoleau P, Cuvier C, Perrocheau G, Ponzio A, Kayitalire L, Pouillart P. Spielmann M, et al. Among authors: ferrero jm. Oncology. 2001;60(4):303-7. doi: 10.1159/000058524. Oncology. 2001. PMID: 11408796 Clinical Trial.

8

Epidermal growth factor receptor expression in 780 breast cancer patients: a reappraisal of the prognostic value based on an eight-year median follow-up.

Ferrero JM, Ramaioli A, Largillier R, Formento JL, Francoual M, Ettore F, Namer M, Milano G. Ferrero JM, et al. Ann Oncol. 2001 Jun;12(6):841-6. doi: 10.1023/a:1011183421477. Ann Oncol. 2001. PMID: 11484962 Free article.

9

Prognostic value of S-phase fraction in 920 breast cancer patients: focus on T1N0 status.

Largillier R, Namer M, Ramaioli A, Ferrero JM, Magné N, Courdi A, Leblanc-Talent P, Formento P, Ettore F, Milano G. Largillier R, et al. Among authors: ferrero jm. Int J Biol Markers. 2003 Oct-Dec;18(4):273-9. doi: 10.5301/jbm.2008.506. Int J Biol Markers. 2003. PMID: 14756542 Free article.

10

A multicenter phase II study of cisplatin and docetaxel (Taxotere) in the first-line treatment of advanced ovarian cancer: a GINECO study.

Diéras V, Guastalla JP, Ferrero JM, Curé H, Weber B, Winckel P, Lortholary A, Mayer F, Paraiso D, Magherini E, Pujade-Lauraine E. Diéras V, et al. Among authors: ferrero jm. Cancer Chemother Pharmacol. 2004 Jun;53(6):489-95. doi: 10.1007/s00280-004-0762-9. Epub 2004 Feb 7. Cancer Chemother Pharmacol. 2004. PMID: 14767617 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

282 results

Search Page